Addario Lung Cancer Medical Institute - ALCMI

11/22/2025

Christine Hann, MD, PhD, of Johns Hopkins Medicine, highlighted significant immunotherapy advancements and persistent challenges in small cell lung cancer at the 20th Annual New York Lung Cancers Symposium.

Christine Hann, MD, PhD, discusses how recently presented SCLC data inform treatment decision-making across the LS-SCLC and ES-SCLC settings.

11/21/2025

DC vaccination combined with atezolizumab has shown encouraging long-term survival in extensive-stage small cell lung cancer.

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

11/20/2025

A multi-institutional team led by Dr. Andreas Rimner has defined the maximum tolerated dose of olaparib combined with thoracic radiotherapy in extensive-stage small cell lung cancer, marking the first clinical demonstration that this radiosensitizing strategy can be delivered safely.

11/19/2025

Congratulations to our friends at Boehringer Ingelheim! The FDA has awarded the company a Commissioner’s National Priority Voucher (CNPV) for zongertinib, recognizing its potential to significantly impact outcomes for patients with HER2 (ERBB2)-mutant non-small cell lung cancer.

Boehringer awarded FDA Commissioner’s National Priority Voucher for zongertinib in patients with HER2-mutant NSCLC

11/18/2025

Synthekine has reported encouraging early results from its Phase Ia/Ib study of STK-012, an interleukin-2 receptor α/β–biased partial agonist, in first-line PD-L1–negative non-squamous non-small cell lung cancer.

11/17/2025

The American Lung Association’s 2025 State of Lung Cancer report shows U.S. five-year survival has risen to 29.7%, yet only 18.2% of eligible adults were screened in 2022, and significant racial disparities persist, underscoring urgent gaps in detection and access to precision care.

Examining lung cancer incidence, survival, stage at diagnosis, surgical treatment, lack of treatment, and screening, this report finds states must do more to protect their residents from lung cancer.

11/16/2025

Radiomics-guided biopsies are an exciting new area that helps define lung cancer heterogeneity.

Solid tumors like lung cancer show significant mutational heterogeneity. A biopsy captures only focal aspects, limiting conclusions about overall tumor biology. This prospective study correlated CT-based radiomics features with genomic profiles to optimize biopsy site selection. Lung cancer patients...

11/15/2025

Artificial intelligence is proving to be a powerful tool in detecting lung cancer and determining who gets screened.

In a recent interview, Hari Kishan Gonuguntla, M.D., discussed AI-powered evaluation of chest X-rays with the Lung Nodule Malignancy Score software and key findings from multinational prospective research presented at the recent ESMO Congress 2025 meeting.

11/14/2025

In a new study published in Cell, Dr. Charles Swanton and the TRACERx Consortium applied personalized liquid biopsy techniques to nearly 3,000 plasma samples from 431 NSCLC patients, revealing that ctDNA levels carry powerful prognostic value both before and after surgery.

Circulating tumor DNA levels before and after surgery provided insights into disease trajectories and clinical outcomes for hundreds of non-small cell lung cancer patients.

11/13/2025

Early data from Memorial Sloan Kettering Cancer Center researchers showed promising efficacy for STK‑012 plus pembrolizumab and chemotherapy in PD‑L1–negative nonsquamous NSCLC.

STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.

11/12/2025

In a new Mayo Clinic article, Dr. Velcheti outlines how advances in precision diagnostics, immunotherapy, and multidisciplinary collaboration are transforming lung cancer outcomes.

Advances in diagnostics, therapeutics, and multidisciplinary care are transforming lung cancer management — marking a pivotal shift toward personalized, evidence-based treatment.

11/11/2025

The FDA has cleared the IND application for ILKN421H (STI-7349), a novel mRNA-based IL-2 variant from iLeukon Therapeutics, to advance into phase 2 studies in advanced non–small cell lung cancer.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.